drugset
Drugs / gp160
last change Oct 1996 re-read 9 days ago

gp160

also known as gp160 vaccine · VaxSyn · gp160 Vaccine (MicroGeneSys) · HIV-1 recombinant envelope glycoprotein gp160 · Immuno-AG · Recombinant GP160 HIV-1 Antigen

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Protein Sciences Corporation · Immuno-US · Bristol-Myers Squibb · Genentech, Inc. · MicroGeneSys Inc (nka Protein Sciences Corporation)

Trials 13

today NCT00000782 · Ph 1 NCT00000762 · Ph 1 NCT00001056 · Ph 1 NCT00000957 · Ph 1 NCT00000968 · Ph 1 NCT00000667 · Ph 1 NCT00000683 · Ph 1 NCT00000977 · Ph 1 NCT00000956 · Ph 1 NCT00000631 · Ph 1 NCT00000630 · Ph 1 NCT00000757 · Ph 1
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 113 trials
Phase 1 NCT00000957 ? → Aug 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000968 ? → Aug 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000956 ? → Mar 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000782 ? → Oct 1996 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001056 ? → Oct 1994 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000977 ? → May 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00002261 — HIV infectious disease Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00000667 ? → Jul 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000683 ? → Jun 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000631 ? → Dec 1992 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as gp160 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000782 ↗
12

NCT00000957 ↗

NCT00000956 ↗

NCT00000667 ↗

NCT00000683 ↗

NCT00002261 ↗

NCT00000630 ↗

NCT00000631 ↗

NCT00000977 ↗

NCT00000968 ↗

NCT00001056 ↗

Show 2 more sources
Known as gp160 vaccine “Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicates that, although serum anti-gp160 antibody responses were detected, the level and...” NCT00000956 ↗
1

“gp160 Vaccine (Immuno-AG)” NCT00001056 ↗
Known as gp160 Vaccine (MicroGeneSys) “gp160 Vaccine (MicroGeneSys)” NCT00000757 ↗
Known as HIV-1 recombinant envelope glycoprotein gp160 “160 mcg HIV-1 recombinant envelope glycoprotein gp160” NCT00000757 ↗
Known as Immuno-AG “gp160 Vaccine (Immuno-AG)” NCT00001056 ↗
Known as Recombinant GP160 HIV-1 Antigen “Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity” NCT00000977 ↗
Known as VaxSyn “Group A (20 volunteers) will receive gp160 (VaxSyn) followed two months later by a repeat dose.” NCT00000630 ↗
1

“soluble recombinant gp160 vaccine (VaxSyn)” NCT00000631 ↗
Modality Vaccine “two candidate HIV vaccines, HIVAC-1e and gp160” NCT00000630 ↗
Route Other “intradermal gp160” NCT00000667 ↗